StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a report released on Thursday morning. The firm issued a hold rating on the stock. Separately, HC Wainwright reiterated a buy rating and set a $18.00 price target on shares of Can-Fite BioPharma in a research report on Thursday, May 9th. Get […]
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Can Fite BioPharma : Immediate Report - MarketScreener marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.